Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9257278 | 0.98 | EPHX1 (0.41) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL2047409 | 0.94 | EPHX1 (0.45) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL1493226 | 0.93 | — | — | |
| SCHEMBL7290456 | 0.92 | EPHX1 (0.48) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL9264950 | 0.92 | EPHX1 (0.44) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL9255771 | 0.90 | EPHX1 (0.47) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL6386082 | 0.87 | EPHX1 (0.47) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL2046996 | 0.86 | — | — | |
| SCHEMBL15822139 | 0.86 | EPHX1 (0.48) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL1526975 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104583280-B | Curability silicon-ketone composition and optical semiconductor device | 道康宁东丽株式会社 | 2017-07-25 | — | — | CN | disclosed |
| CN-104583280-A | Curable silicone composition and optical semiconductor device | DOW CORNING TORAY CO LTD | 2015-04-29 | — | — | CN | disclosed |
| US-7956182-B2 | Process for preparing optically active alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988071-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE ALCOHOL | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC | 2008-08-14 | — | — | US | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1896483-A2 | 4-PIPERAZINYLTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-5455355-A | Postemergence, preemergence herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-10-03 | — | — | US | disclosed |
| US-5401740-A | FOR INHIBITING PLATELET AGGREGATION | OTSUKA PHARMACEUTICAL CO. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5298632-A | Herbicidal pyrimidine compounds, compositions containing the same and method of use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0569592-A1 | CARBOSTYRIL DERIVATIVE AND PLATELET AGGLUTINATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-18 | — | — | EP | disclosed |
| US-5232897-A | Herbicidal pyrimidine compounds, compositions containing the same and method of use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-08-03 | — | — | US | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0457505-A2 | Pyrimidine derivatives and their use as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-11-21 | — | — | EP | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-4704395-A | 5-HYDROXYTRYPTAMINE; HYPOTENSIVES | ELI LILLY AND COMPANY (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0228876-A2 | Esters of dihydrolysergic acid and related compounds | ELI LILLY AND COMPANY (US) | 1987-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | ADH1C, ADH1A, ADH5 | EPHX1 1297/4885LMNA 2508/4885POLB 1478/4885 |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | EPHX1 1020/4885LMNA 2692/4885POLB 2602/4885 |
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFKP, PF4, P2RY4 | EPHX1 1713/4885LMNA 2530/4885POLB 1617/4885 |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | EPHX1 1389/4885LMNA 3156/4885POLB 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.